mRNA is a rapidly evolving area of medicine with huge potential. United by a sense of shared purpose, we’re working with our biopharma clients, 运用创造性思维和高水平的问题解决能力，加速开发和提供可能具有变革性的治疗方法.  为提高产量和使更多患者获得治疗而设计的设施的交付是实现现代医学革命的关键一步.

As the commercialization of autologous cell-therapy products gathers pace, wider access is becoming a reality. To ensure more people around the world can access these innovative treatments, we are partnering with clients to overcome operational and regulatory challenges as they scale out production.

With an increasing number of cell and gene therapy products receiving regulatory approval, there is a burning need to deliver projects that support the growth of groundbreaking treatments. 我们与客户携手合作，提供灵活的设施设计方法，以解决制造商提高生产能力时面临的复杂挑战.

Contract development and manufacturing organizations (CDMOs) are supporting a seismic shift in Life Sciences, with their highly flexible large-scale facilities increasing production capacity on a massive scale, reducing risk for pharma companies, and guaranteeing hyper-speed project delivery. 我们正在帮助CDMO客户通过使用集成项目交付(IPD)实现的灵活方法达到这些以前无法实现的生产目标。.

Flexibility played a central role in the response to COVID-19, 解决方案提供商和生命科学公司以闪电般的速度合作，改造现有的疫苗和治疗设施. This approach is helping to futureproof the sector, enabling companies to scale manufacturing in response to evolving patient needs, 为全球患者提供可能具有变革性的药物、治疗和疗法的快速通道，并满足患者对新治疗和疗法的需求.